# APIs Sector

Canonical URL: https://biopharmsignal.com/sector/apis

APIs refers to active pharmaceutical ingredients, the core chemical or biologic substances used to make medicines. Companies in this category are typically exposed to manufacturing scale, supply reliability, and the economics of pharmaceutical production rather than a single branded asset story.

Companies currently grouped under APIs: 3

## Recent Sector News

- 2026-08-13 05:00 EST — PHAR — [Pharming announces commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with APDS aged 4 and older](https://biopharmsignal.com/news/PHAR/pharming-announces-commercial-launch-of-joenja-leniolisib-in-japan-for-adult-and-15d022ed) — Source: Pharming Group
- 2026-08-04 06:00 EST — PHAR — [Pharming Group to participate in Canaccord Genuity 46th Annual Growth Conference](https://biopharmsignal.com/news/PHAR/pharming-group-to-participate-in-canaccord-genuity-46th-annual-growth-conference-89bea5c1) — Source: Pharming Group
- 2026-07-30 05:00 EST — PHAR — [Pharming reports second quarter and first half 2026 financial results and revises year-end guidance; strong Joenja momentum and near-term clinical readouts to support broader therapeutic use](https://biopharmsignal.com/news/PHAR/pharming-reports-second-quarter-and-first-half-2026-financial-results-and-revise-5218552c) — Source: Pharming Group
- 2026-07-16 06:00 EST — PHAR — [Pharming Group to report second quarter and first half 2026 financial results and provide business update on July 30](https://biopharmsignal.com/news/PHAR/pharming-group-to-report-second-quarter-and-first-half-2026-financial-results-an-f222ee56) — Source: Pharming Group
- 2026-06-04 05:00 EST — PHAR — [Pharming announces U.S. FDA acceptance of sNDA resubmission for Joenja® (leniolisib) to treat children aged 4 to 11 years with APDS](https://biopharmsignal.com/news/PHAR/pharming-announces-u-s-fda-acceptance-of-snda-resubmission-for-joenja-leniolisib-5cf3429e) — Source: Pharming Group
- 2026-06-02 06:00 EST — PHAR — [Pharming Group to participate in Fireside Chat at  2026 Jefferies Global Healthcare Conference in New York](https://biopharmsignal.com/news/PHAR/pharming-group-to-participate-in-fireside-chat-at-2026-jefferies-global-healthca-b0957d70) — Source: Pharming Group
- 2026-05-28 14:40 EST — PHAR — [Pharming Group announces results of 2026 Annual General Meeting of Shareholders](https://biopharmsignal.com/news/PHAR/pharming-group-announces-results-of-2026-annual-general-meeting-of-shareholders-5f53ccfa) — Source: Pharming Group
- 2026-05-22 19:30 EST — PHAR — [European Commission grants marketing authorization to Pharming’s Joenja® (leniolisib) – the first approved treatment for APDS in the European Union](https://biopharmsignal.com/news/PHAR/european-commission-grants-marketing-authorization-to-pharming-s-joenja-leniolis-2d21c32e) — Source: Pharming Group
- 2026-05-07 05:05 EST — PHAR — [Pharming Group announces presentations at CIS 2026 Annual Meeting, including leniolisib pediatric data in APDS and clinical experience in CVID and related disorders](https://biopharmsignal.com/news/PHAR/pharming-group-announces-presentations-at-cis-2026-annual-meeting-including-leni-d8b2c6d4) — Source: Pharming Group
- 2026-05-07 05:00 EST — PHAR — [Pharming Group reports first quarter 2026 financial results; on track for Joenja® U.S. pediatric label expansion and launches in Japan and Europe in 2026](https://biopharmsignal.com/news/PHAR/pharming-group-reports-first-quarter-2026-financial-results-on-track-for-joenja--a75d33bb) — Source: Pharming Group
- 2026-04-23 06:00 EST — PHAR — [Pharming Group to report first quarter 2026 financial results and provide business update on May 7](https://biopharmsignal.com/news/PHAR/pharming-group-to-report-first-quarter-2026-financial-results-and-provide-busine-acfc5345) — Source: Pharming Group
- 2026-04-16 06:00 EST — PHAR — [Pharming Group announces the 2026 Annual General Meeting of Shareholders](https://biopharmsignal.com/news/PHAR/pharming-group-announces-the-2026-annual-general-meeting-of-shareholders-0073995c) — Source: Pharming Group
- 2026-04-07 06:00 EST — PHAR — [Pharming Group to participate in April investor conferences](https://biopharmsignal.com/news/PHAR/pharming-group-to-participate-in-april-investor-conferences-3517e32b) — Source: Pharming Group
- 2026-04-02 05:00 EST — PHAR — [Pharming Group announces the filing of its 2025 Annual Report and Form 20-F](https://biopharmsignal.com/news/PHAR/pharming-group-announces-the-filing-of-its-2025-annual-report-and-form-20-f-f295da9d) — Source: Pharming Group
- 2026-03-27 06:00 EST — PHAR — [Pharming Group receives positive CHMP opinion for Joenja® (leniolisib) for the treatment of APDS in adult and pediatric patients 12 years and older](https://biopharmsignal.com/news/PHAR/pharming-group-receives-positive-chmp-opinion-for-joenja-leniolisib-for-the-trea-f30b6c03) — Source: Pharming Group
- 2026-03-24 06:00 EST — PHAR — [Pharming Group announces approval of Joenja® (leniolisib) in Japan for the treatment of APDS in patients aged 4 years and older](https://biopharmsignal.com/news/PHAR/pharming-group-announces-approval-of-joenja-leniolisib-in-japan-for-the-treatmen-a044b78d) — Source: Pharming Group
- 2026-03-12 06:00 EST — PHAR — [Pharming Group reports fourth quarter and full year 2025 financial results, delivering strong revenue growth and profitability with positive cash flow](https://biopharmsignal.com/news/PHAR/pharming-group-reports-fourth-quarter-and-full-year-2025-financial-results-deliv-f64bbf34) — Source: Pharming Group
- 2026-02-26 07:00 EST — PHAR — [Pharming Group to report fourth quarter and full year 2025 financial results and provide business update on March 12](https://biopharmsignal.com/news/PHAR/pharming-group-to-report-fourth-quarter-and-full-year-2025-financial-results-and-16bb7c03) — Source: Pharming Group
- 2026-02-17 07:00 EST — PHAR — [Pharming Group to present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference](https://biopharmsignal.com/news/PHAR/pharming-group-to-present-at-the-oppenheimer-36th-annual-healthcare-life-science-e361b462) — Source: Pharming Group
- 2026-02-03 06:00 EST — PHAR — [Pharming Group announces 2026 financial guidance and highlights rare disease pipeline at Investor Day](https://biopharmsignal.com/news/PHAR/pharming-group-announces-2026-financial-guidance-and-highlights-rare-disease-pip-96b038fa) — Source: Pharming Group

## Companies

- [CAMX](https://biopharmsignal.com/company/CAMX) — Camurus
- [HNSA](https://biopharmsignal.com/company/HNSA) — Hansa Biopharma AB
- [PHAR](https://biopharmsignal.com/company/PHAR) — Pharming Group